Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...

known as exons, during the process of RNA splicing, causing the body to produce more dystrophin. One of the few other therapeutics focused on exon 53 skipping is NS Pharma’s Viltepso.

It showed a statistically significant increase of 25% in the production of dystrophin ... of exon-skipping therapies for DMD, targeting exons 51, 53, and 45, that brought in around $1 billion ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Corneal diseases can cause severe visual ...